Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Rotundo, Ida Luisa ^a   Faraso, Stefania ^a   de Leonibus, Elvira ^a,b   Nigro, Gerardo ^c   Vitiello, Carmen ^a   Lancioni, Alessio ^a   Napoli, Daniele ^d   Castaldo, Sigismondo ^d   Russo, Vincenzo ^c   Russo, Fabio ^a   Piluso, Giulio ^c   Auricchio, Alberto ^a,e   Nigro, Vincenzo ^a,c  

^a TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; DEFLAZACORT; DELTA SARCOGLYCAN; PREGNANE DERIVATIVE; SARCOGLYCAN;

ADENOVIRUS; ADENOVIRUS 2; ADENOVIRUS 8; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; GENE THERAPY; HEART EJECTION FRACTION; HEART FUNCTION; MALE; MONOTHERAPY; NONHUMAN; PHENOTYPE; TREATMENT DURATION; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS; ANIMAL; ECHOCARDIOGRAPHY; GENE VECTOR; GENETICS; HAMSTER; METABOLISM; SYRIAN HAMSTER; WESTERN BLOTTING;

ADENO-ASSOCIATED VIRUS; ANIMALIA; CRICETINAE; MESOCRICETUS AURATUS;

ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHIES; CRICETINAE; DEPENDOVIRUS; ECHOCARDIOGRAPHY; GENE THERAPY; GENETIC VECTORS; MALE; MESOCRICETUS; PREGNENEDIONES; SARCOGLYCANS;

EID: 80052635987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024729     Document Type: Article

References (45)

1. Nigro G, Comi LI, Politano L, Bain RJ, (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26: 271-277.
2. Manzur AY, Muntoni F, (2009) Diagnosis and new treatments in muscular dystrophies. J Neurol Neurosurg Psychiatry 80: 706-714.
3. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93.
4. Yiu EM, Kornberg AJ, (2008) Duchenne muscular dystrophy. Neurol India 56: 236-247.
5. Politano L, Nigro V, Nigro G, Petretta VR, Passamano L, et al. (1996) Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. Jama 275: 1335-1338.
6. Heydemann A, McNally EM, (2007) Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy. Trends Cardiovasc Med 17: 55-59.
7. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, et al. (1992) Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355: 696-702.
8. Nigro V, Piluso G, Belsito A, Politano L, Puca AA, et al. (1996) Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein. Hum Mol Genet 5: 1179-1186.
9. Vainzof M, Passos-Bueno MR, Canovas M, Moreira ES, Pavanello RC, et al. (1996) The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. Hum Mol Genet 5: 1963-1969.
10. Yoshida M, Noguchi S, Wakabayashi E, Piluso G, Belsito A, et al. (1997) The fourth component of the sarcoglycan complex. FEBS Lett 403: 143-148.
11. Ozawa E, Mizuno Y, Hagiwara Y, Sasaoka T, Yoshida M, (2005) Molecular and cell biology of the sarcoglycan complex. Muscle Nerve 32: 563-576.
12. Nigro V, de Sa Moreira E, Piluso G, Vainzof M, Belsito A, et al. (1996) Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat Genet 14: 195-198.
13. Moreira ES, Vainzof M, Marie SK, Nigro V, Zatz M, et al. (1998) A first missense mutation in the delta sarcoglycan gene associated with a severe phenotype and frequency of limb-girdle muscular dystrophy type 2F (LGMD2F) in Brazilian sarcoglycanopathies. J Med Genet 35: 951-953.
14. Politano L, Nigro V, Passamano L, Petretta V, Comi LI, et al. (2001) Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 11: 178-185.
15. Tsubata S, Bowles KR, Vatta M, Zintz C, Titus J, et al. (2000) Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 106: 655-662.
16. Karkkainen S, Miettinen R, Tuomainen P, Karkkainen P, Helio T, et al. (2003) A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy. J Mol Med 81: 795-800.
17. Nigro V, Okazaki Y, Belsito A, Piluso G, Matsuda Y, et al. (1997) Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 6: 601-607.
18. Homburger F, Baker JR, Nixon CW, Wilgram G, (1962) New hereditary disease of Syrian hamsters. Primary, generalized polymyopathy and cardiac necrosis. Arch Intern Med 110: 660-662.
19. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, et al. (1991) Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 48: 383-388.
20. Angelini C, (2007) The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 36: 424-435.
21. Muntoni F, Fisher I, Morgan JE, Abraham D, (2002) Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research. Neuromuscul Disord 12 (Suppl 1): S162-165.
22. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, et al. (1994) Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 17: 386-391.
23. Rifai Z, Welle S, Moxley RT 3rd, Lorenson M, Griggs RC, (1995) Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol 268: E67-74.
24. Jacobs SC, Bootsma AL, Willems PW, Bar PR, Wokke JH, (1996) Prednisone can protect against exercise-induced muscle damage. J Neurol 243: 410-416.
25. Anderson JE, Weber M, Vargas C, (2000) Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplant 9: 551-564.
26. Kissel JT, Burrow KL, Rammohan KW, Mendell JR, (1991) Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group. Neurology 41: 667-672.
27. Vandebrouck C, Imbert N, Duport G, Cognard C, Raymond G, (1999) The effect of methylprednisolone on intracellular calcium of normal and dystrophic human skeletal muscle cells. Neurosci Lett 269: 110-114.
28. Pasquini F, Guerin C, Blake D, Davies K, Karpati G, et al. (1995) The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromuscul Disord 5: 105-114.
29. Marques MJ, Oggiam DS, Barbin IC, Ferretti R, Santo Neto H, (2009) Long-term therapy with deflazacort decreases myocardial fibrosis in mdx mice. Muscle Nerve 40: 466-468.
30. Silversides CK, Webb GD, Harris VA, Biggar DW, (2003) Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 91: 769-772.
31. Bauer R, Macgowan GA, Blain A, Bushby K, Straub V, (2008) Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy. Cardiovasc Res 79: 652-661.
32. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, et al. (2000) Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2: 619-623.
33. Judge LM, Chamberlain JS, (2005) Gene therapy for Duchenne muscular dystrophy: AAV leads the way. Acta Myol 24: 184-193.
34. Zhu T, Zhou L, Mori S, Wang Z, McTiernan CF, et al. (2005) Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 112: 2650-2659.
35. Vitiello C, Faraso S, Sorrentino NC, Di Salvo G, Nusco E, et al. (2009) Disease rescue and increased lifespan in a model of cardiomyopathy and muscular dystrophy by combined AAV treatments. PLoS One 4: e5051.
36. Sandona D, Betto R, (2009) Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert Rev Mol Med 11: e28.
37. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
38. Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, et al. (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68: 629-638.
39. Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R, (2004) Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 14: 526-534.
40. Markham LW, Spicer RL, Khoury PR, Wong BL, Mathews KD, et al. (2005) Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 26: 768-771.
41. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, et al. (2000) A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23: 1344-1347.
42. Bauer R, Blain A, Greally E, Lochmuller H, Bushby K, et al. (2010) Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. Neuromuscul Disord 20: 21-28.
43. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, et al. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99: 11854-11859.
44. Gao G, Qu G, Burnham MS, Huang J, Chirmule N, et al. (2000) Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther 11: 2079-2091.
45. Sahn DJ, DeMaria A, Kisslo J, Weyman A, (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083.